Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine

References

• Baldwin SJ, Bramhall JL, Ashby CA, Yue L, Murdock PR, Hood SR, Ayrton AD, Clarke SE. Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). Drug Metabolism and Disposition 2006; 34: 1063–1069
   PubMed Web of Science ®Google Scholar
• Fraser DJ, Feyereisen R, Harlow GR, Halpert JR. Isolation, heterologous expression and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. Journal of Pharmacology and Experimental Therapeutics 1997; 283: 1425–1432
   PubMed Web of Science ®Google Scholar
• Hay Kraus BL, Greenblatt DJ, Venkatakrishnan K, Court MH. Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: Reed and gender differences. Xenobiotica 2000; 30: 575–588
   PubMed Web of Science ®Google Scholar
• He P, Court MH, Greenblatt DJ, Von Moltke LL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clinical Pharmacology and Therapeutics 2005; 77: 373–387
   PubMed Web of Science ®Google Scholar
• Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metabolism and Disposition 2002; 30: 1108–1114
   PubMed Web of Science ®Google Scholar
• Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488–1490
   PubMed Web of Science ®Google Scholar
• Komura H, Iwaki M. Species differences in vitro and in vivo small intestinal metabolism of CYP3A substrates. Journal of Pharmaceutical Science 2008; 97: 1775–1800
   PubMed Web of Science ®Google Scholar
• Kukanich B, Lascelles BD, Aman AM, Mealey KL, Papich MG. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. Journal of Veterinary Pharmacology and Therapeutics 2005; 28: 461–466
   PubMed Web of Science ®Google Scholar
• Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metabolism Reviews 2007; 39: 699–721
   PubMed Web of Science ®Google Scholar
• Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metabolism and Disposition 1994; 22: 947–955
   PubMed Web of Science ®Google Scholar
• Lu P, Singh SB, Carr BA, Fang Y, Xiang CD, Rushmore TH, Rodrigues AD, Shou M. Selective inhibition of dog hepatic CYP2B11 and CYP3A12. Journal of Pharmacology and Experimental Therapeutics 2005; 313: 518–528
   PubMed Web of Science ®Google Scholar
• Marathe PH, Rodrigues AD. In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug–drug interactions. Current Opinion in Drug Metabolism 2006; 7: 687–704
   PubMed Web of Science ®Google Scholar
• Neff MW, Robertson KR, Wong AK, Safra N, Broman KW, Slatkin M, Mealey KL, Pedersen NC. Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proceedings of the National Academy of Science USA 2004; 101: 11725–11730
   PubMed Web of Science ®Google Scholar
• Nishibe Y, Wakabayashi M, Harauchi T, Ohno K. Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver. Xenobiotica 1998; 28: 549–557
   PubMed Web of Science ®Google Scholar
• Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 ‘pie’. Drug Metabolism and Disposition 2006; 34: 880–886
   PubMed Web of Science ®Google Scholar
• Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapeutics 1997; 283: 1552–1562
   PubMed Web of Science ®Google Scholar
• Paulson SK, Engel L, Reitz B, Bolten S, Burton EG, Maziasz TJ, Yan B, Schoenhard GL. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metabolism and Disposition 1999; 27: 1133–1142
   PubMed Web of Science ®Google Scholar
• Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y, Mei Q, Rodrigues AD, Rushmore TH. Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. Drug Metabolism and Disposition 2003; 31: 1161–1169
   PubMed Web of Science ®Google Scholar
• Smith BJ, Zupan LA, Hu JK, Diters RW, Gibson GW, Norton JN. Characterization of the effects of tebufelone on hepatic cytochromes P450 in the beagle dog. Drug Metabolism and Disposition 1996; 24: 523–528
   PubMed Web of Science ®Google Scholar